A Clinical Trial to Evaluate the Efficacy and Safety of DR-2011 for In Vitro Fertilization

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00615251
Recruitment Status : Completed
First Posted : February 14, 2008
Last Update Posted : September 13, 2013
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Duramed Research )

Brief Summary:
This is a multi-center study to evaluate the effects of DR-2011 compared to a progesterone gel in women undergoing in vitro fertilization with fresh eggs. The overall study duration will be approximately 12 months and will involve ovarian suppression/stimulation protocols as well as egg retrieval.

Condition or disease Intervention/treatment Phase
Infertility Drug: DR-2011 Drug: Crinone 8% Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1297 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Phase 3, Single-Blind, Randomized Study to Compare DR-2011 to a Progesterone Gel for Luteal Phase Supplementation for In Vitro Fertilization
Study Start Date : February 2008
Actual Primary Completion Date : August 2009
Actual Study Completion Date : August 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 Drug: DR-2011
Progesterone vaginal ring for approximately 10 weeks
Active Comparator: 2 Drug: Crinone 8%
progesterone vaginal gel for approximately 10 weeks

Primary Outcome Measures :
  1. Clinical pregnancy rate at 8 weeks and 12 weeks of pregnancy [ Time Frame: 8 weeks of pregnancy (6 weeks after egg retrieval) and 12 weeks of pregnancy (10 weeks after egg retrieval) ]

Secondary Outcome Measures :
  1. Secondary outcome measures will include: live birth rate, cycle cancellation rate, rate of spontaneous abortion, rate of biochemical pregnancy, rate of ectopic pregnancy [ Time Frame: Duration of study ]
  2. Adverse events [ Time Frame: Duration of study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 42 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Pre-menopausal, aged 18-42 old at time of consent
  • At least one cycle without fertility medication prior to screening
  • Tubal, idiopathic, male factor, ovulatory dysfunction or endometriosis- linked infertility
  • Semen analysis (frozen sperm, including donor sperm, may be used, as long as testing done at time of freezing meets standard criteria)
  • Others as indicated by FDA-approved protocol

Exclusion Criteria:

  • Any contraindication to progesterone therapy
  • BMI > 38 kg/m2
  • Clinically significant gynecologic pathology (for example: submucosal fibroids, abnormal uterine cavity, or others)
  • History of more than 1 failed fresh IVF cycles
  • More than 2 consecutive clinical miscarriages (gestational sac observed on ultrasound)
  • Others as indicated by FDA-approved protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00615251

  Show 29 Study Locations
Sponsors and Collaborators
Duramed Research
Study Chair: Duramed Research Protocol Chair Duramed Research, Inc.

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Duramed Research Identifier: NCT00615251     History of Changes
Other Study ID Numbers: DR-PGN-302
First Posted: February 14, 2008    Key Record Dates
Last Update Posted: September 13, 2013
Last Verified: August 2013

Keywords provided by Teva Pharmaceutical Industries ( Duramed Research ):
In vitro fertilization

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs